Molecular Signatures in COVID-19 Disease Spectrum

This pilot study proposes to use the Yale IMPACT Biorepository to identify metabolic signatures in the plasma of a SARS-CoV-2-infected patient that may predict the severity of COVID-19 experience by the patient. The proposed studies will distinguish how metabolic changes and clinical symptoms/parameters relate to each other (both within and between each patient group) and thereby provide insights into potential mechanisms underlying the observed changes. Study findings would be extremely helpful for triaging patients and allowing for more efficient utilization of limited health resources, e.g. medications, ventilators, ICU beds, and medical personnel.